Prognostic value of [

Non-small cell lung cancer PET imaging lung adenocarcinoma prognosis surgery

Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
14 Feb 2020
Historique:
entrez: 15 2 2020
pubmed: 15 2 2020
medline: 15 2 2020
Statut: aheadofprint

Résumé

To evaluate the prognostic role of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) measured by FDG-positron emission tomography (PET)/computed tomography (CT) in patients with primary lung adenocarcinoma undergoing surgical resection. All consecutive patients undergoing curative surgery for primary lung adenocarcinoma at the Thoracic Surgery Unit of the University Hospital of Parma between January 2009 and December 2014 were retrospectively analyzed. The cutoff point of each continuous PET parameter was determined through receiver operating characteristic curve and Youden index, using overall survival (OS) as the classification status. Univariate and multivariate Cox proportional hazards models were applied to evaluate the association between OS and potential prognostic variables, including SUVmax, MTV, and TLG. A total of 193 patients were considered eligible for this study. The mean 5-year OS rate was 70.5 ± 3.5%. Acinar and lepidic patterns were more frequently associated with absent or low (<2.5) SUVmax values [ In this study, [

Identifiants

pubmed: 32056506
doi: 10.1177/0300891620904404
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

300891620904404

Auteurs

Luigi Ventura (L)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Maura Scarlattei (M)

Nuclear Medicine Unit, University Hospital of Parma, Parma, Italy.

Letizia Gnetti (L)

Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.

Enrico Maria Silini (EM)

Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.

Maurizio Rossi (M)

Department of Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy.

Marcello Tiseo (M)

Medical Oncology, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.

Nicola Sverzellati (N)

Section of Radiology, Diagnostic Department, University Hospital of Parma, Parma, Italy.

Giovanni Bocchialini (G)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Luca Musini (L)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Valeria Balestra (V)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Luca Ampollini (L)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Michele Rusca (M)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Paolo Carbognani (P)

Thoracic Surgery, Department of Vascular, Cardiac and Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Livia Ruffini (L)

Nuclear Medicine Unit, University Hospital of Parma, Parma, Italy.

Classifications MeSH